Status:
UNKNOWN
Study of Tapering and Discontinuing Biological DMARDs in Rheumatoid Arthritis Patients
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20-90 years
Brief Summary
This study aims to analyses time to disease relapse of RA patients if TNF-α inhibitors are being tapered, the predictive factors that are associated with successful taper of TNF-α inhibitors. Also, in...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosed of RA based on the 1987 American College of Rheumatology (ACR) criteria and/or 2010 ACR/EULAR classification criteria of RA depending on the time of diagnosis Age ≥ 20 years old TNF-α inhibitors was prescribed for RA patients refractory to csDMARDs (defined as csDMARD therapy for over 6 months) during 2003/5/2 - 2017/4/30 Dose reduction or discontinuation use of TNF-α inhibitors (2011/1/1-2019/4/30)
- Exclusion criteria:
- TNF-α inhibitors were discontinued or tapered due to adverse events such as infection, liver transaminase elevation, malignancy and neutropenia.
Exclusion
Key Trial Info
Start Date :
December 3 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04472390
Start Date
December 3 2019
End Date
December 1 2021
Last Update
July 15 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Zhongzheng District, Taiwan, 100